Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01777152
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT01760226
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01746173
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Rongjie Tao
- Target Recruit Count
- 16
- Registration Number
- NCT01735747
- Locations
- 🇨🇳
Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 87
- Registration Number
- NCT01719835
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 3300
- Registration Number
- NCT01704716
- Locations
- 🇵🇱
Medical University in Gdansk, Gdansk, Poland
🇵🇱Children's University Hospital in Lublin, Lublin, Poland
🇵🇱University of Medical Sciences Poznan, Poznan, Poland
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University College, London
- Target Recruit Count
- 129
- Registration Number
- NCT01679119
- Locations
- 🇬🇧
North Hampshire Hospital, Basingstoke, United Kingdom
🇬🇧West Suffolk Hospital, Bury St Edmunds, United Kingdom
🇬🇧University Hospital, Coventry, Coventry, United Kingdom
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 671
- Registration Number
- NCT01659099
- Locations
- 🇧🇪
Clinique universitaire Saint LUC, Bruxelles, Belgium
🇧🇪CHU Ambroise Paré, Mons, Belgium
🇧🇪Clinique Sainte Elisabeth, Namur, Belgium
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01622439
- Locations
- 🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 8
- Registration Number
- NCT01542736
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.